TY - JOUR
T1 - Structure and inhibition of the SARS coronavirus envelope protein ion channel
AU - Pervushin, Konstantin
AU - Tan, Edward
AU - Parthasarathy, Krupakar
AU - Lin, Xin
AU - Jiang, Feng Li
AU - Yu, Dejie
AU - Vararattanavech, Ardcharaporn
AU - Tuck, Wah Soong
AU - Ding, Xiang Liu
AU - Torres, Jaume
PY - 2009/7
Y1 - 2009/7
N2 - The envelope (E) protein from coronaviruses is a small polypeptide that contains at least one a-helical transmembrane domain. Absence, or inactivation, of E protein results in attenuated viruses, due to alterations in either virion morphology or tropism. Apart from its morphogenetic properties, protein E has been reported to have membrane permeabilizing activity. Further, the drug hexamethylene amiloride (HMA), but not amiloride, inhibited in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. We have previously shown for the coronavirus species responsible for severe acute respiratory syndrome (SARS-CoV) that the transmembrane domain of E protein (ETM) forms pentameric a-helical bundles that are likely responsible for the observed channel activity. Herein, using solution NMR in dodecylphosphatidylcholine micelles and energy minimization, we have obtained a model of this channel which features regular a-helices that form a pentameric left-handed parallel bundle. The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM. Full length SARS-CoV E displayed channel activity when transiently expressed in human embryonic kidney 293 (HEK-293) cells in a whole-cell patch clamp set-up. This activity was significantly reduced by hexamethylene amiloride (HMA), but not by amiloride. The channel structure presented herein provides a possible rationale for inhibition, and a platform for future structure-based drug design of this potential pharmacological target.
AB - The envelope (E) protein from coronaviruses is a small polypeptide that contains at least one a-helical transmembrane domain. Absence, or inactivation, of E protein results in attenuated viruses, due to alterations in either virion morphology or tropism. Apart from its morphogenetic properties, protein E has been reported to have membrane permeabilizing activity. Further, the drug hexamethylene amiloride (HMA), but not amiloride, inhibited in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. We have previously shown for the coronavirus species responsible for severe acute respiratory syndrome (SARS-CoV) that the transmembrane domain of E protein (ETM) forms pentameric a-helical bundles that are likely responsible for the observed channel activity. Herein, using solution NMR in dodecylphosphatidylcholine micelles and energy minimization, we have obtained a model of this channel which features regular a-helices that form a pentameric left-handed parallel bundle. The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM. Full length SARS-CoV E displayed channel activity when transiently expressed in human embryonic kidney 293 (HEK-293) cells in a whole-cell patch clamp set-up. This activity was significantly reduced by hexamethylene amiloride (HMA), but not by amiloride. The channel structure presented herein provides a possible rationale for inhibition, and a platform for future structure-based drug design of this potential pharmacological target.
UR - http://www.scopus.com/inward/record.url?scp=70049096788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70049096788&partnerID=8YFLogxK
U2 - 10.1371/journal.ppat.1000511
DO - 10.1371/journal.ppat.1000511
M3 - Article
C2 - 19593379
AN - SCOPUS:70049096788
SN - 1553-7366
VL - 5
JO - PLoS Pathogens
JF - PLoS Pathogens
IS - 7
M1 - e1000511
ER -